Home » Authors » Nuala Moran

Nuala Moran

Articles

ARTICLES

CEOs Wary Of Proposal In UK To Tighten Governance Rules

Sep. 3, 2003

Research Group Grows UK's First Embryonic Stem Cell Line

Aug. 27, 2003

Celltech Ends Development Of CDP 571 In Crohn's Indication

Aug. 27, 2003

Research Group Grows UK's First Embryonic Stem Cell Line

Aug. 27, 2003

Celltech Ends Development Of CDP 571 In Crohn's Indication

Aug. 27, 2003

Xenova Adding To Pipeline Via £8.5M KS Biomedix Acquisition

Aug. 20, 2003

Xenova Adding To Pipeline Via £8.5M KS Biomedix Acquisition

Aug. 20, 2003

LONDON - Consolidation continues in the UK as Xenova Group plc announced an agreed-to £8.48 million (US$13.5 million) all-share takeover offer for KS Biomedix plc (KSB). (BioWorld International)

Xenova Adding To Pipeline Via £8.5M KS Biomedix Acquisition

Aug. 20, 2003

Xenova Adding To Pipeline Via £8.5M KS Biomedix Acquisition

Aug. 20, 2003

LONDON - Consolidation continues in the UK as Xenova Group plc announced an agreed-to £8.48 million (US$13.5 million) all-share takeover offer for KS Biomedix plc (KSB). (BioWorld International)

Alizyme Enters $42M Deal With Takeda, Its First Collaboration

Aug. 13, 2003

View All Articles by Nuala Moran

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.